Blog: Blog2

GPCR News

Trevena Reports Second Quarter 2022 Results and Provides Business Update

August 2022 "CHESTERBROOK, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the...

Aug 1, 20221 min read

7 views

0 comments

April 2022 Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group...

Apr 1, 20221 min read

2 views

0 comments

April 2022 Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with...

Apr 1, 20221 min read

1 view

0 comments

February 2022 Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical...

Feb 1, 20221 min read

6 views

0 comments

December 2021 "3-part randomized, double-blind, placebo-controlled Phase 1 study will evaluate TRV045 safety, tolerability, and PK in...

Dec 1, 20211 min read

3 views

0 comments

November 2021 "November 11, 2021 7:00am EST Patricia Drake appointed new Chief Commercial Officer CHESTERBROOK, Pa., Nov. 11, 2021 --...

Nov 1, 20211 min read

1 view

0 comments